Brief: Regulus Therapeutics Announces Completion Of Enrollment In Fourth Cohort Of Phase 1B Multiple-Ascending Dose Clinical Trial
08/10/2024 13:07
Oct 8 (Reuters) - Regulus Therapeutics Inc RGLS.O :
* REGULUS THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT IN
FOURTH COHORT OF PHASE 1B MULTIPLE-ASCENDING DOSE (MAD) CLINICAL
TRIAL OF RGLS8429 FOR THE TREATMENT OF PATIENTS WITH AUTOSOMAL
DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
* REGULUS THERAPEUTICS INC: REMAIN ON TRACK FOR AN END OF
PHASE 1
MEETING WITH FDA BY END OF 2024
* REGULUS THERAPEUTICS INC - PLANS TO SHARE TOPLINE DATA IN
EARLY
2025
Source text for Eikon: ID:nPnb6RKPPa
Further company coverage: RGLS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Regulus Therapeutics
See all newsBrief: Novartis Completes Acquisition Of Regulus Therapeutics
Brief: Novartis Announces Expiration Of Hart-Scott-Rodino Waiting Period Of Regulus Therapeutics Tender Offer
Brief: Novartis Announces Commencement Of Tender Offer To Acquire Regulus Therapeutics
Regulus Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Regulus Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview